Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 2 of the 7 sources its claims cite were checked for support.
Abstract
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in September 2020 and is rapidly spreading toward fixation. Using a variety of statistical and dynamic modeling approaches, we estimate that this variant has a 43 to 90% (range of 95% credible intervals, 38 to 130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine rollout, COVID-19 hospitalizations and deaths across England in the first 6 months of 2021 were projected to exceed those in 2020. VOC 202012/01 has spread globally and exhibits a similar transmission increase (59 to 74%) in Denmark, Switzerland, and the United States.
Overview
CoChat Summary
TL;DR
Using sequencing, mobility/contact data, and dynamic transmission models, the paper finds that SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01) spread substantially faster than prior lineages in England. The authors estimate it is 43 to 90% more transmissible, with no clear evidence of increased disease severity, but warn that faster spread would increase cases, hospitalizations, and the need for stronger control measures and faster vaccination.
Key findings
- In UK sequencing data, VOC 202012/01 had the highest relative population growth rate among 307 other lineages in the first 31 days after initial phylogenetic observation, and it continued to expand.
- A multinomial spline model estimated an increased growth rate of +0.104 day–1 relative to B.1.177, corresponding to a 77% increase in reproduction number R (95% CI, 73 to 81%) assuming a 5.5-day generation interval.
- Alternative analyses estimated R for VOC 202012/01 to be 43% higher (95% CI, 38 to 48%) from case-based regression, and 55% higher in Denmark, 74% higher in Switzerland, and 59% higher in the United States.
- The transmission model found no clear increase or decrease in severity, with odds ratios of 0.92 for hospitalization, 0.90 for critical illness, and 0.90 for death, but estimated transmissibility was 65% higher in the three most affected NHS regions and 82% higher across all seven regions.
Methods
- The study combined publicly available sequencing data from COG-UK, Pillar 2 testing data for S gene target failure, mobility data from Google Community Mobility, and social contact data from the CoMix survey, plus analogous sequence/RT-PCR data from Denmark, Switzerland, and the US.
- The authors used multinomial and binomial generalized linear mixed models, negative binomial state-space models, and an age- and region-structured deterministic compartmental transmission model fitted to multiple regional data streams, including deaths, hospital admissions, bed occupancy, PCR prevalence, seroprevalence, and VOC frequency.
- They compared five mechanistic hypotheses for the rapid spread, assessed model fit with deviance information criteria and short-term prediction, and ran scenario projections under varying NPIs and vaccination rollout rates.
Limitations
- The paper states that only a small number of intervention and vaccination scenarios were considered, and these should not be viewed as the only policy options.
- It states that the transmission model does not explicitly capture nursing home or hospital transmission, and regions were fit separately rather than jointly modeling between-region transmission.
- It notes uncertainty in model choice and parameter assumptions, including school-closure assumptions and NPI efficacy; these are limitations stated in the paper.
- Evident from the text: the severity analysis is based on early population-level data up to 24 December 2020, so delays from infection to hospitalization or death could obscure severity effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Measuring the growth rate of VOC 202012/01. (A) Average relativized growth rate (i.e., a measure of variant fitness relative to other variants present during the 31 days after initial phylogenetic observation of a given variant) for all lineages in the COG-UK dataset, highlighting many lineages that have risen to prominence including B.1.177, the lineage with the highest relative abundance during the initial phylogenetic observation of VOC 202012/01. The shaded regions show conservative 95% rejection intervals; VOC 202012/01 is the first strain to exceed this threshold of faster relativized growth. Although many lineages exhibit above-average rates of growth, VOC 202012/01 has had the highest average relativized growth of any lineage in the history of COG-UK surveillance of SARS-COV-2. (B) Plotting all lineages’ relativized growth rates [ρ(t)] as a function of lineage age with conservative 95% rejection intervals highlights the significantly faster growth of VOC 202012/01 relative to other lineages at comparable times since their initial observation. Later declines in VOC and B.1.177 correspond to highly uncertain estimates of growth rates for data that are yet to be backfilled, so these declines in ρ(t) are sensitive to the processing of future sequences from recent dates (fig. S1). (C) Muller plots of the relative abundances of the major SARS-CoV-2 variants in the UK, based on a multinomial spline fit to COG-UK sequence data (Table 1 and table S1, separate-slopes multinomial spline model). A model extrapolation until 1 March 2021 is shown (shaded area). Minority variants are 440 circulating SARS-CoV-2 variants of low abundance. Specific colors represent the same lineages in (A) to (C). (D) Mean reproduction number over 7-day periods in 149 upper-tier local authorities of England (colored by the NHS England region they are within) plotted against the weekly proportion of Pillar 2 community SARS-CoV-2 tests with S gene target failure shows the spread of VOC 202012/01, a corresponding increase in the reproduction number in each local authority, and the eventual impact of targeted government restrictions from 20 December 2020. Testing data are shown for the week after the reproduction number estimates to account for delays from infection to test.](https://figures.cochat.ai/paper-figures/6a959b32b94b41a4aab77f4b47b25a40/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-2.jpg)
![Fig. 3 Comparison of possible biological mechanisms underlying the rapid spread of VOC 202012/01. Each row shows a different assumed mechanism. (A) Relative frequency of VOC 202012/01 (black line and ribbon respectively denote observed S gene target failure frequency with 95% binomial credible interval; purple line and ribbon respectively denote mean and 95% credible interval from model fit). (B) Posterior estimates (mean and 95% credible intervals) for relative odds of hospitalization (severe illness), relative odds of ICU admission (critical illness), relative odds of death (fatal illness), growth rate as a multiplicative factor per week [i.e., exp(7·∆r)], and the parameter that defines the hypothesized mechanism; all parameters are relative to those estimated for preexisting variants. (C to E) Illustrative model fits for the South East NHS England region: (C) fitted two-strain increased transmissibility model with VOC 202012/01 included; (D) fitted two-strain increased transmissibility model with VOC 202012/01 removed; (E) fitted single-strain model without emergence of VOC 202012/01. Black lines denote observed data; error bars denote the date range and 95% credible intervals for observed PCR prevalence and seroprevalence; colored lines and ribbons denote median and 95% credible intervals from model fit.](https://figures.cochat.ai/paper-figures/806d848e45ca40c19e0cc853e2b24dfc/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-3.jpg)

Verification
Claims the paper makes
2 Valid · 0 Not valid · 4 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we did not find substantial differences in social interactions between regions of high and low VOC 202012/01 prevalence, as measured by Google mobility (11) and social contact survey data (12) from September to December 2020 (Fig. 1, E and F).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
What the sources say
- Not matchedcites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Methods (Survey methodology) identify this as the CoMix social-contact survey, supporting the citation’s identification of the survey. But the Results (Participant characteristics) say the data reported here were collected on 24–27 March 2020; this paper does not establish that its reported data cover September–December 2020. The comparison between regions is presented as the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This yielded an estimated increase in R for VOC 202012/01 of 43% (95% CI, 38 to 48%), increasing to a 57% (95% CI, 52 to 62%) increase if the spline was not included (Table 1, models 4a and 4b).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants.”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Discussion Combining multiple behavioral and epidemiological data sources with statistical and dynamic modeling, we estimated that the SARS-CoV-2 variant VOC 202012/01 has a 43 to 90% (range of 95% CrIs, 38 to 130%) higher reproduction number than preexisting variants of SARS-CoV-2 in England, assuming no changes to the generation interval. On the basis of early population-level data, we were unable to identify whether the new variant is associated with higher disease severity. Theoretical considerations suggest that, in some cases, natural selection may favor reduced severity of disease in pathogens (23). For this to be true, however, the pathogen’s infectious period must be truncated by disabling symptoms or death often enough that a less-virulent mutant generates more secondary infections despite potentially being less transmissible per contact, to the extent that decreased virulence and decreased transmissibility are consequences of the same mutation (e.g., one that decreases viral load). It is far from clear that this condition holds for SARS-CoV-2, given substantial transmission before the onset of severe symptoms. Regardless, without strengthened controls, there is a clear risk that future epidemic waves may be larger—and hence associated with greater burden—than previous waves. The UK government initiated a third national lockdown on 5 January 2021 in response to the rapid spread of VOC 202012/01, including school closures. Educational settings are among the largest institutions linked to SARS-CoV-2 clusters that remained open during the November 2020 lockdown (24), which means that the enacted school and university closures may have substantially assisted in reducing the burden of COVID-19 in early 2021. The increase in transmission associated with VOC 202012/01 has crucial implications for vaccination. First, it means that prompt and efficient vaccine delivery and distribution are even more important to reduce the impact of the pandemic in the near future. Increased transmission resulting from VOC 202012/01 will raise the herd immunity threshold, so that the potential burden of SARS-CoV-2 is larger and higher vaccine coverage will be required to achieve herd immunity. It is therefore extremely concerning that VOC 202012/01 has spread to at least 114 countries globally (2). Although VOC 202012/01 was first identified in England, a rapidly spreading variant has also been detected in South Africa (25, 26), where there was a marked increase in transmission in late 2020. Another variant exhibiting immune escape has emerged in Brazil (27, 28). Thus, vaccination timelines will also be a crucial determinant of future burden in other countries where similar new variants are present. Second, there is a need to assess how VOC 202012/01 and other emerging lineages affect the efficacy of vaccines (29, 30). Vaccine developers may need to consider developing formulations with variant sequences, and they may want to initiate post-licensure studies to detect differences in efficacy between the preexisting and new variants. Licensing authorities may need to clarify abbreviated pathways to marketing for vaccines that involve altering strain formulation without any other changes to their composition. There are limitations to our analysis. We have considered a small number of intervention and vaccination scenarios, which should not be regarded as the only available options for policy-makers. Our transmission model does not explicitly capture nursing home or hospital transmission of SARS-CoV-2, and we fit the model to each region of England separately rather than pooling information across regions and explicitly modeling transmission between regions. There are also uncertainties in the choice of model used to generate these predictions, and the exact choice will yield differences in the measures needed to control the epidemic. We note that even without increased susceptibility of children to VOC 202012/01, the more efficient spread of the variant implies that the difficult societal decision of closing schools will be a key public health question for multiple countries in the months ahead. We only assess relative support in the data for the mechanistic hypotheses proposed, but there may be other plausible mechanisms driving the resurgence of cases that we did not consider, and we have not identified the specific combination of mechanisms driving the increased transmission of VOC 202012/01. We identify increased transmissibility as the most parsimonious mechanistic explanation for the higher growth rate of VOC 202012/01, but a longer infectious period also fits the data well (table S4) and is supported by longitudinal testing data (17). Our conclusions about school closures were based on the assumption that children had reduced susceptibility and infectiousness relative to adults (19), but the precise values of these parameters and the impact of school closures remain the subject of scientific debate (31). We based our assumptions about the efficacy of NPIs on the measured impact on mobility of previous national lockdowns in England, but the impact of policy options cannot be predicted with certainty. Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants. Our modeling analysis suggests that this difference could be explained by an overall higher infectiousness of VOC 202012/01, but not by a shorter generation time or immune escape alone. Further experimental work will provide insight into the biological mechanisms for our observations, but given our projections of a rapid rise in incidence from VOC 202012/01—and the detection of other novel and highly transmissible variants (25–28)—there is an urgent need to consider what new approaches may be required to sufficiently reduce the ongoing transmission of SARS-CoV-2.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the relative population growth rate of VOC 202012/01 in the first 31 days after its initial phylogenetic observation was higher than that of all 307 other lineages with enough observations to obtain reliable growth-rate estimates (Fig. 2A and fig. S1).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
plainn = 150,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of COVID-19 cases attributable to VOC 202012/01 increased rapidly in all regions of England, following an initial expansion in the southeast (Fig. 1A)”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 43 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom.”
From New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, viral variants of concern have emerged in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several emerging viral variants of concern have been identified that have mutations in the spike protein, including the B.1.1.7 variant (originating from the UK and which has eight spike mutations92), the B.1.351 variant (originating from South Africa) and the P.1 variant (originating from Brazil and which also contains multiple mutations in the spike protein and is spreading widely)57,93.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“it has been previously reported that B.1.1.7 is associated with lower Ct values, corresponding to higher VLs 3”
From Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (2021) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Markov Processes: Characterization and Convergence
Ethier, S. N., & Kurtz, T. G. (1986) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316658 · Cited by 3,634
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Advanced Bayesian Multilevel Modeling with the R Package brms
Bürkner, P.-C. (2018) · The R Journal · doi:10.32614/rj-2018-017 · Cited by 3,015 · cited 9×
“168) 67 (53-83) 120 (92-152) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE North West VOC vs.”
BackgroundMethodInfluentialSocial Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900 · cited 10×
“105) 43 (40-46) 72 (67-78) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London VOC vs.”
BackgroundInfluentialSelf-citationProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 8×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundResultInfluentialEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Self-citationA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 10×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundInfluential
Cited by
Items 1,501–1,600 of 2,327
Evolution of SARS-CoV-2 Spikes shapes their binding affinities to animal ACE2 orthologs
Yao, W., Li, Y., Ma, D., Hou, X.-D., Wang, H., Tang, X., Cheng, D., Zhang, H., Du, C., Pan, H., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02676-23 · Cited by 6
“In spite of these tremendous global efforts and achievements, the continuous emergence of SARS-CoV-2 variants of concern (VOCs) (17–24) with more and more enhanced community transmission and immune evasion poses great challenges to the control of the pandemic, which shows no sign of termination in…”
BackgroundFunction and mechanism of bispecific antibodies targeting SARS-CoV-2
Li, Z., Zhang, Z., Rosen, S. T., & Feng, M. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100150 · Cited by 5
“Within a short span, a mutation occurring at position N501Y in the spike protein emerged (Brown et al., 2021; Davies et al., 2021; Graham et al., 2021; Socher et al., 2021; Volz et al., 2021), setting off subsequent mutations at various sites, including the variants of concern (VOCs) and variants…”
BackgroundGræsbøll, K., Eriksen, R. S., Kirkeby, C., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00621-9 · Cited by 5
Evolution of virulence in emerging epidemics: from theory to experimental evolution and back
Benhamou, W., Blanquart, F., Choisy, M., et al. (2024) · Virus Evolution · doi:10.1093/ve/veae069 · Cited by 5
“…prevalence, deaths, hospital admissions) and genetic data (e.g., strain frequencies) quantified variants properties such as transmission, virulence, infectious period, immune escape or generation interval distribution – e.g., (Benhamou et al., 2023; Blanquart et al., 2022; Davies et al., 2021).”
BackgroundDarling, H. S., Parikh, P. M., Vaishnav, R., Verma, A., Gulia, A., Kapoor, A., & Singh, R. K. (2021) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_14_2021 · Cited by 5
Oroszi, B., Horváth, J. K., Túri, G., et al. (2021) · Scientia et Securitas · doi:10.1556/112.2021.00007 · Cited by 5
Pandemic planning: Developing a triage framework for Neonatal Intensive Care Unit
Daboval, T., Williams, C., & Albersheim, S. (2021) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2021.06.014 · Cited by 5
“Although the COVID-19 pandemic has not yet seen severe disease in infants and children, it has brought the issue of pandemic planning to the fore, particularly as novel COVID-19 variants emerge, with more rapid spread and some evidence that they are more marked in children, highlighting the importance of pandemic plan…”
Epidemiological Risk Factors for Acquiring Severe COVID-19: Prospective Cohort Study
Awaidy, S. T. A., Khamis, F. A., Mahomed, O. H., Wesonga, R., Shuabi, M. A., Shabibi, N. S. A., Dhahli, D. S. A., Noumani, J. A., Alhadidi, A. M., & Wahebi, M. A. (2021) · Oman Medical Journal · doi:10.5001/omj.2021.127 · Cited by 5
The emergence, dynamics and significance of SARS-CoV-2 variants
Colson, P., Parola, P., & Raoult, D. (2022) · New Microbes and New Infections · doi:10.1016/j.nmni.2022.100962 · Cited by 5
“For SARS-CoV-2, this was neglected for several months and we first reported the existence of variants in early September 2020 [5], three months before the term variant was adopted in December 2020 for the Alpha variant [6].”
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031646 · Cited by 6
Smith, D. R., Singh, C., Green, J., Lueder, M. R., Arnold, C. E., Voegtly, L. J., Long, K. A., Rice, G. K., Luquette, A. E., Miner, H. L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836658 · Cited by 5
“The Alpha variant was initially detected in the United Kingdom at the end of 2020 and remained as the dominant strain globally until May 2021 (2).”
BackgroundDeepSARS: simultaneous diagnostic detection and genomic surveillance of SARS-CoV-2
Yermanos, A., Hong, K., Agrafiotis, A., Han, J., Nadeau, S., Agüí, C. V., Azizoğlu, A., Ehling, R. A., Gao, B., Spahr, M. E., et al. (2022) · BMC Genomics · doi:10.1186/s12864-022-08403-0 · Cited by 5
Kumar, A., Ladha, A., Choudhury, A., Ikbal, A. M. A., Bhattacharjee, B., Das, T., Gupta, G., Sharma, C., Sarbajna, A., Mandal, S. C., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2081156 · Cited by 6
Clinical Profile of Coronavirus Disease 2019 Comparing the First and Second Waves
Chhabra, S., Sethi, S., Kaur, S. P., et al. (2022) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_691_21 · Cited by 5
“For example, the SARS‑CoV‑2 lineage B.1.1.7, which was first detected in the United Kingdom in November 2020, is estimated to be 40%–80% more transmissible than the wild‑type SARS‑CoV‑2.”
BackgroundInfluentialGlatman‐Freedman, A., Feldman, S. F., Hershkovitz, Y., Kaufman, Z., Dichtiar, R., Keinan‐Boker, L., & Bromberg, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac524 · Cited by 6
“13 Transmissibility can vary among different SARS-CoV-2 variants (25-27).”
Backgroundvan Beek, J., Teesing, G. R., Munnink, B. B. O., Meima, A., Vriend, H. J., Elzakkers, J., de Graaf, M., Langeveld, J., Medema, G. J., Molenkamp, R., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276696 · Cited by 7
Relative Infectivity of the SARS-CoV-2 Omicron Variant in Human Alveolar Cells
Kim, T., Min, K. I., Yang, J., Kim, J. W., Cho, J., Kim, Y. H., Lee, J. S., Kim, Y. T., Kim, K.-C., Kim, J. Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105571 · Cited by 5
“Taewoo Kim (1)*, Kyoung Il Min (1)*, Jeong-Sun Yang (2), Jun Won Kim (2), Junhyung Cho (2), Yun Ho Kim (3), Jeong Seok Lee (1,4), Young Tae Kim (3), Kyung-Chang Kim(2), Jeong Yeon Kim (4), Kwon Joong Na (3)#, Joo-Yeon Lee (2) #, Young Seok Ju (1,4,5) #”
Park, H., Park, Y.-J., Lee, S., Lee, M. J., & Ahn, H. (2022) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2022.0243 · Cited by 5
“Furthermore, these findings could support the hypothesis that exposure to a high viral load for a long period is associated with a high incidence rate [ 29].”
Brown, K. L., Ceci, A., Roby, C. D., Briggs, R., Ziolo, D., Korba, R., Mejia, R., Kelly, S., TONEY, D. M., Friedlander, M. J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2154617 · Cited by 5
Feng, J., Zhu, W., Ye, X., Liu, Z., Zhu, Y., Wu, Q., Yang, G., & Wang, W. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-022-07967-2 · Cited by 4
Scheithauer, S., Dilthey, A., Bludau, A., et al. (2023) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-023-03680-w · Cited by 5
Foxley-Marrable, M., D'Cruz, L. G., Meredith, P., Glaysher, S., Beckett, A. H., Goudarzi, S., Fearn, C., Cook, K. F., Loveson, K. F., Dent, H., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283447 · Cited by 5
“Admission Age 76 [63, 85] 74 [60, 85] 80 [68, 86] 82 [73, 88] 63 [54, 71] 64 [56, 71]”
Haque, S., Mathkor, D. M., Alkhanani, M., Bantun, F., Momenah, A. M., Faidah, H. S., Jalal, N. A., & Kumar, V. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2194007 · Cited by 6
“These variants are also demonstrated to increase transmissibility (Davies et al., 2021), alter infectivity (Li et al., 2020; L. Zhang et al., 2020), ineffective towards neutralizing antibodies and escape from neutralization (Dejnirattisai et al., 2021; Mannar et al., 2022; Wibmer et al., 2021; Xie…”
BackgroundSARS-CoV-2 Variants Impact on Key Signaling Pathways Metamorphoses into Severity
Misra, G., Hora, S., Ginwal, S., Singh, N. K., & Anvikar, A. R. (2023) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2023220261 · Cited by 5
“This was first identified in United Kingdom after the sequencing of SARS-CoV-2 positive samples of patients in late December 2020 [31].”
BackgroundGenomic Diversity and Evolution of SARS-CoV-2 Lineages in Pakistan
Aziz, M. W., Mukhtar, N., Anjum, A. A., Mushtaq, M. H., Ashraf, M. A., Nasir, A., Shahid, M. F., Nawaz, M., Shabbir, M. Z., Sarwar, N., et al. (2023) · Viruses · doi:10.3390/v15071450 · Cited by 5
Cavallaro, M., Dyson, L., Tildesley, M. J., Todkill, D., & Keeling, M. J. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2023.0410 · Cited by 5
“Historically, these data permitted the observation of SARS-CoV-2 Alpha variant spreading and becoming the dominant lineage in few months after being first detected in September 2020 [22,23].”
ResultGlobal Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread
Ajmera, H., Lakhawat, S. S., Malik, N., Kumar, A., Bhatti, J. S., Kumar, V., Gogoi, H., Jaswal, S. K., Chandel, S., & Sharma, P. K. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037274719231212044235 · Cited by 5
Scarpa, F., Branda, F., Petrosillo, N., & Ciccozzi, M. (2024) · Infectious Disease Reports · doi:10.3390/idr16020024 · Cited by 5
“Phylodynamic reconstruction indicated a high level of variability with an exponential growth of lineages until May–June 2021 [8,9].”
BackgroundBatista-Roche, J. L., Mirabent-Casals, M., Manzanares, D., Lund, G., & García-Gasca, A. (2024) · COVID · doi:10.3390/covid4040032 · Cited by 6
Bayer, D., Goldstein, I., Fintzi, J., Lumbard, K., Ricotta, E., Warner, S., Strich, J. R., Chertow, D. S., Busch, L. M., Parker, D. M., et al. (2024) · The Annals of Applied Statistics · doi:10.1214/24-aoas1882 · Cited by 8
Impffortschritt in Deutschland und der Welt: Chancen und Risiken
Grimm, V., Lembcke, F. K., & Schwarz, M. (2021) · Wirtschaftsdienst · doi:10.1007/s10273-021-2894-5 · Cited by 5
Hu, B., Liu, R., Tang, X., Pan, Y., Wang, M., Tong, Y., Ye, G., Shen, G., Ying, R., Fu, A., et al. (2021) · National Science Review · doi:10.1093/nsr/nwab073 · Cited by 5
Neuman, B. W., Brashear, W. A., Brun, M., Chaki, S. P., Fischer, R. S. B., Guidry, S. J., Hill, J. E., Hillhouse, A., Johnson, C. D., Kahl-McDonagh, M. M., et al. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0542 · Cited by 6
Tam, J. S., Shu, Y., & Asia Pacific Alliance for the Control of Influenza (APACI), S. M. (2022) · China CDC Weekly · doi:10.46234/ccdcw2021.228 · Cited by 5
Whole-genome sequencing of SARS-COV-2 showed wide spread of B.1.525 in February 2021 in Libya
Alhudiri, I. M., Ramadan, A. M., Ibrahim, K. M., Abdalla, A., ElJilani, M. M., Salem, M. A., Elgheriani, H. M., Meshri, S. E. E., & Elzagheid, A. I. (2021) · Libyan Journal of Medicine · doi:10.1080/19932820.2021.2001210 · Cited by 5
Potential therapeutic application of mesenchymal stem cells in COVID-19 complications
Kolanko, E., Mazurski, A., & Czekaj, P. (2021) · Medycyna Pracy · doi:10.13075/mp.5893.01207 · Cited by 5
“It has been shown to be highly sensitive to immunization with the Pfizer-BioNTech vaccine, but patients may become infected within 2 weeks after receiving the first dose and within 1 week after receiving the second dose [27].”
BackgroundUnderstanding how fast SARS-CoV-2 variants transmit from household studies
Yang, Y., & Kenah, E. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00053-6 · Cited by 5
Luo, R., Guo, P., Shang, M., Cai, Y., Huang, J., He, Y., Mo, P. K. H., Wu, A. M. S., Xu, R. D., Li, J., et al. (2022) · Internet Interventions · doi:10.1016/j.invent.2022.100541 · Cited by 5
Modelling the effect of COVID-19 mass vaccination on acute hospital admissions
Booton, R. D., Powell, A. L., Turner, K., et al. (2022) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzac031 · Cited by 5
Yu, W., Drzymalla, E., GWINN, M. L., & Khoury, M. J. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07219-3 · Cited by 6
Phylogenetic and amino acid signature analysis of the SARS-CoV-2s lineages circulating in Tunisia
Sassi, M. B., Ferjani, S., Mkada, I., Arbi, M., Safer, M., Moussi, A. E., Abid, S., Souiai, O., Gharbi, A., Tejouri, A., et al. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105300 · Cited by 7
LHSPred: A web based application for predicting lung health severity
Bhattacharjee, S., Saha, B., Bhattacharyya, P., et al. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.103745 · Cited by 5
“The high rate of reproduction of these variants results in a higher rate of infections [2].”
BackgroundLata, S., & Akif, M. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30276 · Cited by 5
“7 was first detected in the United Kingdom in September 2020 and has been reported with 7 mutations in the Spike protein.(8,12) Within a month a South African variant was detected with 9 mutations.”
BackgroundZavascki, A. P., Vieceli, T., Wink, P. L., Volpato, F. C. Z., Monteiro, F. L., Willig, J. B., Ferreira, C. F., Arns, B., Costa, G. O. M., Niches, M. D. S., et al. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-1264 · Cited by 5
Nava, G. R., Egoryan, G., Dong, T., Zhang, Q., Hyser, E., Poudel, B., Yanez‐Bello, M. A., Trelles-Garcia, D. P., Chung, C. W., Pyakuryal, B., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07555-4 · Cited by 7
Corrao, G., Franchi, M., Cereda, D., Bortolan, F., Leoni, O., Jara, J., Valenti, G., & Pavesi, G. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13551 · Cited by 6
Ciuffreda, L., González‐Montelongo, R., Alcoba-Flórez, J., de Artola, D. G.-M., Gil-Campesino, H., Rodríguez‐Pérez, H., Íñigo-Campos, A., de Miguel-Martínez, I., Tosco-Núñez, T., Díez-Gil, O., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.919346 · Cited by 11
“This lineage has been associated with increased transmissibility (Davies et al., 2021; Volz et al., 2021) compared to the previously circulating variants, a feature that has been linked to the presence of the mutation N501Y in the Spike (S) receptor-binding domain (RBD).”
BackgroundBowie, C., & Friston, K. J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.999210 · Cited by 6
How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
Pons, S., Uhel, F., Frapy, E., Sérémé, Y., Zafrani, L., Aschard, H., & Skurnik, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10477-y · Cited by 6
“After spreading in the UK, this variant has then been detected in different parts of the world [105], was estimated to be associated with 50–70% more transmissibility [106] and might also be associated with more lethality [107].”
BackgroundChristensen, J., Davidovski, F. S., Skaarup, K. G., Lassen, M. C. H., Alhakak, A. S., Sengeløv, M., Nielsen, A. B., Johansen, N. D., Bundgaard, H., Hassager, C., et al. (2022) · Cardiology · doi:10.1159/000528308 · Cited by 5
Kwon, T., Gaudreault, N. N., Meekins, D. A., McDowell, C. D., Cool, K. R., & Richt, J. A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03301-22 · Cited by 6
Bahlmann, N. A., Mautner, L., Hoyos, M., Sallard, E., Berger, C., Dangel, A., Jönsson, F., Fischer, J., Kreppel, F., Zhang, W., et al. (2023) · Genes · doi:10.3390/genes14071348 · Cited by 5
Rezaei, Z., Asaei, S., Sepehrpour, S., Jamalidoust, M., Namayandeh, M., Norouzi, F., & Pourabbas, B. (2023) · Health Science Reports · doi:10.1002/hsr2.1373 · Cited by 4
“All three variants of Alpha, Beta, and Gamma have a mutation at N501Y in which the amino acid asparagine (N) has been replaced by tyrosine (Y) at position 501 in the RBD of the spike protein, making the virus more contagious through facilitating spike protein binding to cellular receptors.(14,15) In addition, two vari…”
BackgroundResultSheikhi, F., & Kowsari, Z. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282624 · Cited by 8
“The transmission rate of this variant has been increased by 43 to 90% compared to the initial COVID-19 generation [11].”
BackgroundResultInfluentialMolecular biology of SARS-CoV-2 and techniques of diagnosis and surveillance
Ishige, T. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.11.003 · Cited by 7
Lakhia, R. T., & Trivedi, J. (2024) · F1000Research · doi:10.12688/f1000research.145771.1 · Cited by 3
What we know and don’t know on SARS-CoV-2 and COVID-19
Silva-Ayarza, I., & Bachelet, V. C. (2021) · Medwave · doi:10.5867/medwave.2021.04.8198 · Cited by 7
L’Huillier, A. G., Ardura, M. I., Chaudhuri, A., Danziger‐Isakov, L. A., Dulek, D. E., Green, M., Michaels, M. G., Posfay-Barbe, K. M., Vásquez, L., & Benden, C. (2021) · Pediatric Transplantation · doi:10.1111/petr.14031 · Cited by 5
Small-world effects in a modified epidemiological model with mutation and permanent immune mechanism
Cao, S., Feng, P., Wang, W., Shi, Y., & Zhang, J. (2021) · Nonlinear Dynamics · doi:10.1007/s11071-021-06519-8 · Cited by 4
Ebanks, D., Faustini, S. E., Shields, A. M., Parry, H., Moss, P. A. H., Plant, T. D., Richter, A. G., & Drayson, M. T. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.07.020 · Cited by 4
Koopsen, J., Dekker, M., Thung, P., Jonges, M., Vennema, H., Leenstra, T., Eggink, D., Welkers, M. R. A., Struijs, P. A. A., Reusken, C. B. E. M., et al. (2021) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-021-01008-4 · Cited by 5
Caruso, P., Testa, R. S., Freitas, I. C. L., Praça, A. P. A., Okamoto, V. N., Santana, P. V., Costa, R. T., Kawasaki, A. M., Fumis, R. R. L., Illanes, W. A. P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.746431 · Cited by 5
“7) (33, 34) and the Brazilian Gamma (former P.”
BackgroundFlannagan, J., Twohig, K. A., Carter, E., Chudasama, D. Y., Lamagni, T. L., & Dabrera, G. (2022) · Epidemiology · doi:10.1097/ede.0000000000001497 · Cited by 5
Ginseng Protects ACE2-Transgenic Mice from SARS-CoV-2 Infection
Seo, S. H. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2706180 · Cited by 6
“, originating in the United Kingdom, showed an increased transmission rate and high mortality in infected humans [8].”
BackgroundStidsen, J. V., Green, A., Rosengaard, L., & Højlund, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1025699 · Cited by 5
“7 lineage was associated with an increased risk of transmission (48), increased risk of hospitalization (25) and increased risk of mortality (49, 50), which could have had an impact on the differences seen between wave 1 and 2.”
BackgroundModeling the impact of the Omicron infection wave in Germany
Maier, B. F., Burdinski, A., Wiedermann, M., Rose, A. H., Schlosser, F., der Heiden, M. A., Wichmann, O., Harder, T., & Brockmann, D. (2023) · Biology Methods and Protocols · doi:10.1093/biomethods/bpad005 · Cited by 5
Hogan, C. A., Sbihi, H., Jassem, A. N., Prystajecky, N., Tyson, J. R., Lee, T. D., Tsang, F., Ng, C., Janz, L., Romney, M. G., et al. (2021) · medRxiv · doi:10.1101/2021.03.23.21253520 · Cited by 4
Evaluating and optimizing COVID-19 vaccination policies: a case study of SwedenPreprint
Sjödin, H., Rocklöv, J., & Britton, T. (2021) · medRxiv · doi:10.1101/2021.04.07.21255026 · Cited by 5
“7 originating from the UK, which has become increasingly dominant in 25 Europe and Sweden and estimated to have a 39-130% higher reproduction number 26 (3), and has been suggested to cause more severe illness (4).”
BackgroundGarushyants, S., Rogozin, I. B., & Koonin, E. V. (2021) · Research Square · doi:10.21203/rs.3.rs-456574/v1 · Cited by 5
Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448459 · Cited by 5
The Intergenerational Mortality Tradeoff of COVID-19 Lockdown Policies
Ma, L., Shapira, G., de Walque, D., Do, Q., Friedman, J. A., & Levchenko, A. A. (2021) · World Bank, Washington, DC eBooks · doi:10.1596/1813-9450-9677 · Cited by 6
Taiwan on track to end third COVID-19 community outbreakPreprint
Nordling, T. E. M., & Wu, Y.-H. (2021) · medRxiv · doi:10.1101/2021.06.20.21259178 · Cited by 5
“[4] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al.”
BackgroundBhatia, S., Wardle, J., Nash, R. K., Nouvellet, P., & Cori, A. (2021) · medRxiv · doi:10.1101/2021.11.26.21266899 · Cited by 4
Panovska‐Griffiths, J., Swallow, B., Hinch, R., et al. (2022) · medRxiv · doi:10.1101/2021.12.30.21267090 · Cited by 5
Self-citationInsights into the limited global spread of the immune evasive SARS-CoV-2 variant MuPreprint
Petrone, M. E., Lucas, C. G. D. O., Menasché, B. L., Breban, M. I., Yildirim, I. B., Campbell, M., Omer, S. B., Ko, A. I., Grubaugh, N. D., Iwasaki, A., et al. (2022) · medRxiv · doi:10.1101/2022.03.28.22273077 · Cited by 5
Reiner, R. C., Collins, J. K., anon Forecasting Team, & Murray, C. J. L. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4126660 · Cited by 5
Geographic migration and vaccine-induced fitness changes of Streptococcus pneumoniaePreprint
Belman, S., Lefrancq, N., Nzenze, S. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.18.524577 · Cited by 5
The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysisPreprint
Stoddard, M., Lin, Y., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2023) · medRxiv · doi:10.1101/2023.01.26.23285076 · Cited by 5
Narechania, A., Bobo, D., Deitz, K. C., DeSalle, R., Planet, P. J., & Mathema, B. (2024) · Genome Research · doi:10.1101/gr.278594.123 · Cited by 6
“Alpha swept the population in March 2021 (Davies et al. 2021), Delta by July 2021 (Kläser et al. 2022), and Omicron by January 2022 (Paton et al. 2022).”
Su, Y. C. F., Zeller, M. A., Ou, T. P., Ma, J., Pum, L., Zhang, R., Rath, S., Heang, V., Kol, S., Lim, R., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00685-7 · Cited by 6
“…canonical mutations like the 69/70 deletion and N501Y substitution in the spike protein, that are known to confer increased transmissibility 9,49 spike 69/70 deletion facilitates faster syncytium formation through improvedfusogenicity 49 andtheN501Ysubstitutioninthereceptorbinding domain…”
Communicating wastewater-based surveillance data to drive action
Farkas, K., Kaya, D., Maal‐Bared, R., Al-Mustapha, A. I., Tandukar, S., Keenum, I. M., Gunnar, T., Bivins, A. W., Wade, M. J., Bibby, K. J., et al. (2025) · Journal of Water and Health · doi:10.2166/wh.2025.080 · Cited by 4
Optimal non-pharmaceutical intervention policy for Covid-19 epidemic via neuroevolution algorithm
Saeidpour, A., & Rohani, P. (2021) · Evolution, Medicine and Public Health · doi:10.1093/emph/eoac002 · Cited by 4
“emergence of new variants with higher transmissibility [39] which gave rise to a faster 246 depletion of the susceptible pool than accounted for in our model.”
ResultCOVID-19 and Influenza: Differences, Similarities, and Coinfection
Shirvani, F., Babaie, D., & Karimi, A. M. (2022) · Archives of Pediatric Infectious Diseases · doi:10.5812/pedinfect.114358 · Cited by 4
Radiomorphological signs and clinical severity of SARS-CoV-2 lineage B.1.1.7
Simon, J., Grodecki, K., Cadet, S., Killekar, A., Slomka, P. J., Zara, S. J., Zsarnóczay, E., Nardocci, C., Nagy, N., Kristóf, K., et al. (2022) · BJR|Open · doi:10.1259/bjro.20220016 · Cited by 4
Du, F., Zhang, W., Yao, H., Xia, Y., Zhang, X., Yang, P., & Ning, P. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01470-1 · Cited by 4
Roy, D. R., Rahman, M. M., Chaity, A. S., Reza, M. A., & Haque, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-18302-9 · Cited by 4
Hassam, M., Bashir, M. A., Shafi, S., Zahra, N. U. A., Khan, K., Jalal, K., Siddiqui, H. L., & Uddin, R. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106284 · Cited by 6
Optimization of Vaccination Clinics to Improve Staffing Decisions for COVID-19: A Time-Motion Study
Wang, X., Pan, J., Liu, Z., et al. (2022) · Vaccines · doi:10.3390/vaccines10122045 · Cited by 4
Gupta, A., Basu, R., & Bashyam, M. D. (2023) · Access Microbiology · doi:10.1099/acmi.0.000513.v3 · Cited by 3
“…emergence of multiple virus variants [2, 3], of which five were classified as Variants of Concern (VoCs) by the WHO (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) based on their higher transmissibility [4–7] and/or enhanced ability to escape neutralization by antibodies [8–13].”
Noorimotlagh, Z., Mirzaee, S. A., Seif, F., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40342-y · Cited by 4
SARS-CoV-2 HaploGraph: visualization of SARS-CoV-2 haplotype spread in Japan
Nakagawa, S., Katayama, T., Jin, L., Wu, J., Kryukov, K. A., Oyachi, R., Takeuchi, J. S., Fujisawa, T., Asano, S., Komatsu, M., et al. (2023) · Genes & Genetic Systems · doi:10.1266/ggs.23-00085 · Cited by 3
“Alpha variants were not only more transmissible than pre-existing SARS-CoV-2 variants but also caused more severe illness and increased mortality (Challen et al., 2021; Grint et al., 2021; Davies et al., 2021).”
BackgroundZhang, Q., Yang, Y., Lan, J., Wang, Z., Gao, Y., Li, X., Mao, W., Xie, J., Mi, L.-Z., Zhang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259386 · Cited by 5
Visual analysis of hotspots and trends in long COVID research based on bibliometric
Lai, Z., Pu, T., Li, J., Bai, F., Wu, L., & Tang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24053 · Cited by 6
“Nevertheless, the UK Office for National Statistics (ONS) showed that the 5-week prevalence of any symptoms of long COVID in SARS-CoV-2-positive patients from April 22 to December 14, 2020 was 22.1 %, while the 12-week prevalence was 9.9 % [52].”
BackgroundInfluentialA proposed analytical approach to estimate excess daily mortality rates in Ecuador
Fernández-Naranjo, R., Vásconez-González, J., Izquierdo‐Condoy, J. S., Landazuri-Navas, S., Castillo, D., & Ortiz‐Prado, E. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1250343 · Cited by 4
Brudenell, E. L., Pohare, M. B., Zafred, D., Phipps, J., Hornsby, H. R., Darby, J. F., Dai, J., Liggett, E., Cain, K. M., Barran, P. E., et al. (2024) · Biochemical Journal · doi:10.1042/bcj20240019 · Cited by 6
Päll, T., Abroi, A., Avi, R., Niglas, H., Shablinskaja, A., Pauskar, M., Jõgeda, E., Soeorg, H., Kallas, E., Lahesaare, A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303176 · Cited by 4
“The B.1.1.7 lineage was more highly-transmissible than its pre-VOC predecessors, resulting in its worldwide spread, and this became dominant in a large number of countries [20–22].”
BackgroundInfluentialSocial contacts in Switzerland during the COVID-19 pandemic: Insights from the CoMix study
Reichmuth, M. L., Heron, L., Beutels, P., Hens, N., Low, N. N., & Althaus, C. L. (2024) · Epidemics · doi:10.1016/j.epidem.2024.100771 · Cited by 6
Advancements in the Development of Anti-SARS-CoV-2 Therapeutics
Huang, J., Ma, Q., Su, Z., & Cheng, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910820 · Cited by 6
“Data indicates that the transmissibility of the Alpha variant has quickly outpaced that of previously existing variants of the novel coronavirus in the UK, establishing it as the predominant new variant in the country [31,38].”
BackgroundAnalysis of the immune response in COVID-19
Hromić‐Jahjefendić, A., & Aljabali, A. A. A. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.10.004 · Cited by 4
Prediction of COVID-19 cases by multifactor driven long short-term memory (LSTM) model
Shao, Y., Wan, T. K., & Chan, K. H. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-86698-1 · Cited by 6
Metadata
- Authors
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E., & Edmunds, W. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Selva Analytics LLC, Bozeman, MT, USA.
- KU Leuven (BE)
- Pennsylvania State University (US)
- Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
- Corresponding author
- Davies, Nicholas G.
- ORCID
- Davies, Nicholas G.
- Abbott, Sam
- Barnard, Rosanna C.
- Jarvis, Christopher I.
- Kucharski, Adam J.
- Munday, James D.
- Pearson, Carl A. B.
- Russell, Timothy W.
- Tully, Damien C.
- Washburne, Alex D.
- Wenseleers, Tom
- Gimma, Amy
- Waites, William
- Wong, Kerry L. M.
- van Zandvoort, Kevin
- Silverman, Justin D.
- Diaz-Ordaz, Karla
- Keogh, Ruth
- Eggo, Rosalind M.
- Funk, Sebastian
- Jit, Mark
- Atkins, Katherine E.
- Edmunds, W. John
- Venue
- Science
- Published
- 2021-04-09
- Volume
- 372
- Issue
- 6538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8128288
- OpenAlex
- W3134208712
- Semantic Scholar
- 34e9a0b4e42a4971a3a124c818045741c734fb9e
- Cited by
- 2,581
- References
- 58
- Citations by year
- 2026: 74 · 2025: 102 · 2024: 199 · 2023: 330 · 2022: 840 · 2021: 1028
- FWCI
- 215.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion, cc-by)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Kentucky
- Universität Bern
- Universitätsspital Basel
- National Institute for Health Research (NIHR200908)
- European Commission (101003688)
- CANDU Owners Group
- Hôpitaux Universitaires de Genève
- Eidgenössische Technische Hochschule Zürich
- Université de Sfax
- UKRI Research England (NA)
- National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR200929)
- United Kingdom Medical Research Council (MC_PC_19065)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- SARS-CoV-2, B.1.1.7 variant, reproduction number, SARS-CoV-2 transmission, epidemic forecasting, COVID-19 containment measures, vaccine rollout, school closures, England
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Communicable Disease Control, England, Europe, Female, Humans, Infant, Male, Middle Aged, Models, Theoretical, Mutation, Severity of Illness Index, Socioeconomic Factors, United States, Viral Load, Basic Reproduction Number, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.